Advertisement

Cancer Immunology, Immunotherapy

, Volume 62, Issue 5, pp 975–981 | Cite as

Toward next-generation cancer immunotherapy: 10th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23–25, 2012

  • Björn-Philipp KlokeEmail author
  • Sarah Kutscher
  • Richard Rae
  • Pia Kvistborg
  • Cedrik M. Britten
  • Sine Reker Hadrup
Meeting Report

Introduction

With 620 international participants, more than 70 speakers and 216 abstracts, the 2012 Annual Meeting of the Association for Cancer Immunotherapy (CIMT) celebrated its 10th anniversary as the premier European meeting dedicated to research and development of cancer immunotherapy. The latest advances of the field were discussed in sessions on cellular therapies, immunomonitoring, new targets and leads, therapeutic vaccination, tumor biology and immune interaction. Here, we summarize the highlights of the meeting which were representative of the newest advances and trends in the field of cancer immunotherapy.

Personalized medicine

The 10th anniversary meeting especially highlighted the path to personalized cancer therapy. Translating promising research concepts into the clinic still faces a myriad of challenges. The complex application of novel technologies, biomarkers and immune monitoring, the demands of GMP manufacturing as well as regulatory questions continue to test...

Keywords

Circulate Tumor Cell Cancer Immunotherapy Chimeric Antigen Receptor BRAF Inhibitor Adoptive Cell Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

The authors declare that they have no conflict of interest. Cedrik Britten has been co-organizer of the meeting.

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Björn-Philipp Kloke
    • 1
    Email author
  • Sarah Kutscher
    • 2
  • Richard Rae
    • 3
  • Pia Kvistborg
    • 4
  • Cedrik M. Britten
    • 1
    • 3
  • Sine Reker Hadrup
    • 5
  1. 1.Ribological GmbHMainzGermany
  2. 2.Immatics Biotechnologies GmbHTübingenGermany
  3. 3.TRON–Translational Oncology at the University Medical Center of the Johannes Gutenberg UniversityMainzGermany
  4. 4.The Netherlands Cancer InstituteAmsterdamThe Netherlands
  5. 5.Center for Cancer Immune Therapy (CIMT)University Hospital HerlevHerlevDenmark

Personalised recommendations